Can Combination MEK and Akt Inhibition Slay the Giant Congenital Nevus?

Area of Science:

• Dermatology
• Oncology
• Molecular Biology

Background:

• Large and giant congenital melanocytic nevi (lgCMN) present significant clinical challenges.
• Current management primarily involves extensive surgical interventions.
• There is a need for novel therapeutic strategies to control lgCMN proliferation.

Purpose of the Study:

• To investigate the efficacy of targeted therapies in limiting lgCMN proliferative potential.
• To evaluate the use of MEK and Akt inhibitors in a preclinical lgCMN model.

Main Methods:

• Utilized lgCMN explants for in vitro studies.
• Developed and employed a patient-derived xenograft model for in vivo assessment.
• Administered MEK and Akt inhibitors locally to the lgCMN models.

Main Results:

• Local administration of MEK and Akt inhibitors significantly reduced the proliferative capacity of lgCMN.
• The xenograft model demonstrated the therapeutic potential of these targeted agents.
• Findings suggest a new avenue for lgCMN treatment.

Conclusions:

• Targeted inhibition of MEK and Akt pathways shows promise in managing lgCMN.
• These findings support further research into targeted therapies as an adjunct or alternative to surgery for lgCMN.